Odimma Therapeutics develops ODI-2001, a first-in-class personalized immunotherapy candidate for cancer. The company completed proof-of-activity experiments of ODI-2001 in several hard-to-treat preclinical cancer models and has secured the pharmaceutical process for production. Pharmaceutical partnerships support key components of the product: myNEO for neoepitope prediction by AI, Touchlight Genetics for synthetic DNA production, and ABL Europe for the viral component. Current activities focus on preparation of a Phase I First-in-Man clinical trial in patients with advanced solid tumors, including regulatory interactions, toxicology and clinical operations. R&D activities are being strengthened to generate additional data and intellectual property. The company recently raised financing to support these clinical preparations and is actively working on its next financing round.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

May 2023